ARES Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ARES is a reasonable long-term hold, but it is not a strong immediate buy for a beginner right now. The stock has supportive fundamental catalysts and mostly positive Wall Street sentiment, but the technical setup is only neutral and the options market is leaning cautious. Given the user wants to buy now and not wait for a better entry, my direct view is to hold off on adding aggressively today and only buy if already willing to own it for the long term.
The trend is neutral to mildly constructive. Price closed at 124.6, just above the pivot of 124.072 and below the first resistance at 128.098. RSI_6 at 55.36 is neutral, showing no overbought condition. MACD histogram is -0.304 and still below zero, though the negative momentum is contracting, which suggests weakening downside pressure rather than a confirmed breakout. Moving averages are converging, pointing to a sideways-to-slightly bullish setup rather than a strong trend. Short-term pattern data also looks mixed, with limited next-day and one-month upside probability.
["Ares raised about $850 million for its first closed-end real estate debt fund, targeting $1.5 billion total.", "Ares completed a joint venture with The Scion Group to acquire a 12-property off-campus student housing portfolio for about $910 million.", "Recent news shows continued capital formation, fundraising, and deployment activity.", "Congress trading data is positive overall, with 2 purchase transactions versus 1 sale transaction in the last 90 days.", "BofA added Ares to its US 1 List, which is a favorable institutional signal."]
["Several analysts cut price targets after Q1, showing tempered near-term expectations.", "Q1 earnings quality was described as weak or lumpy, with misses tied to fee-related performance revenues and base management fees.", "Options positioning is bearish-leaning, with put-call ratios above 1.0.", "Hedge fund and insider trading trends are neutral with no strong buying trend.", "Short-term pattern analysis suggests limited near-term upside and possible softness over the next month."]
No usable financial snapshot was provided due to an error, so latest-quarter revenue or earnings growth cannot be assessed directly. From analyst commentary, the latest quarter appears to have been mixed: Ares missed on after-tax realized net income and some fee-related metrics, but beat on fundraising and deployments. The latest quarter referenced in the data is Q1 2026, and the market seems to be focusing more on fundraising momentum and long-term earnings power than on the quarter’s weaker earnings quality.
Wall Street remains broadly positive, with multiple Buy/Outperform/Overweight ratings still in place. However, the trend in price targets is downward: TD Cowen lowered to $144 from $148, BofA to $142 from $148, Oppenheimer to $146 from $147, Barclays raised to $140 from $127, JPMorgan cut sharply to $144 from $188, Citizens lowered to $190 from $205, and Morgan Stanley cut to $163 from $178 with an Equal Weight rating. Overall, pros still like the long-term franchise, fundraising strength, and private credit positioning, but they are reducing targets due to macro pressure and lower near-term earnings quality. That makes the Street constructive on the business, but less enthusiastic on the stock at current levels.
